Dichoptic Virtual Reality Therapy for Amblyopia in Adults
NCT ID: NCT02246556
Last Updated: 2017-05-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
17 participants
INTERVENTIONAL
2014-10-31
2016-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trial Comparing Patching With Active Vision Therapy to Patching With Control Vision Therapy as Treatment for Amblyopia
NCT00587171
Assessment of Device for Treatment of Amblyopia
NCT02003235
Effectiveness of Virtual Reality Training in Amblyopia
NCT05732467
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
NCT06380517
The Effect of Light Deprivation on Visual Functions in Adult Amblyopes
NCT02799836
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patching therapy
Patching treatment followed by crossover to dichoptic virtual reality video game treatment arm using Diplopia (TM) software developed for the Oculus Rift (R) game system.
Patching therapy
Conventional patching therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software
Dioptic (non-dichoptic) therapy
Dioptic (non-dichoptic) therapy followed by crossover to dichoptic virtual reality video game treatment arm using Diplopia (TM) software developed for the Oculus Rift (R) game system.
Dioptic (non-dichoptic) therapy
Dioptic (non-dichoptic) video game therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software
Dichoptic therapy
Dichoptic virtual reality video game treatment using Diplopia (TM) software developed for the Oculus Rift (R) game system.
Dichoptic therapy
Dichoptic virtual reality video game therapy with Diplopoia (TM) software developed for the Oculus Rift (R) gaming system
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dichoptic therapy
Dichoptic virtual reality video game therapy with Diplopoia (TM) software developed for the Oculus Rift (R) gaming system
Patching therapy
Conventional patching therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software
Dioptic (non-dichoptic) therapy
Dioptic (non-dichoptic) video game therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 15-40
* Anisometropic amblyopia or strabismic amblyopia
* Best corrected visual acuity of 20/30 or worse in the amblyopic eye
* No prior therapeutic use of the software
* No other ongoing therapies including patching or recent eye muscle surgery
* No vested interest in the product
* Ability attend visits and complete the training session, and to stop the intervention after the specified intervention period
Exclusion Criteria
* Organic lesions of the eye preventing the establishment of good vision (eg. media opacities, abnormalities in the fundus or optic nerve).
* Lesions of the brain preventing the establishment of good vision (eg. cortical visual impairment).
* Establishment of normal vision by refractive adaptation (wearing glasses after presentation).
* Patients diagnosed with Photosensitive Epilepsy.
* Inability to comply with the follow-up visits required.
* History of pathologic nystagmus (congenital or sensory).
15 Years
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, San Francisco
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marc Levin
Assistant Professor, Neuro-ophthalmology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California, San Francisco
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
093955
Identifier Type: OTHER
Identifier Source: secondary_id
14-14212
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.